News & Analysis as of

Biotechnology › Committee on Foreign Investment in the United States › China

Pillsbury Winthrop Shaw Pittman LLP

Congress Sets Sights on Limiting Access to Chinese Biotech Companies

Pillsbury Winthrop Shaw Pittman LLP on

The BIOSECURE Act would prohibit federal agencies from contracting with, extending loans to, or awarding grants to, any company with existing or pending agreements with identified biotechnology companies. This limits funding...more

Foley Hoag LLP

CFIUS Year in Review

Foley Hoag LLP on

CFIUS reviewed a record number of transactions in 2021 according to its most recent annual report – and shows no signs of slowing down. High technology (including quantum computing), life sciences, and green energy...more

Sheppard Mullin Richter & Hampton LLP

New Year, New Development: Fewer Industries May be Affected by Proposed Outbound Investment Controls (Reverse CFIUS)

Sheppard Mullin Richter & Hampton LLP on

Occasionally, on our blog, we allow ourselves to indulge in prognostication. Similarly, and also occasionally, we are wrong. Nevertheless, we hope to distinguish ourselves by our candor and admit our misses....more

American Conference Institute (ACI)

[Webinar] CFIUS in the Time of Covid-19: Addressing Dealmakers’ Top 5 Biggest Questions - May 19th, 1:00 pm - 2:00 pm EST

American Conference Institute (ACI) on

Looking for authoritative information about the latest developments and challenges the current crisis will raise in CFIUS? During these uncertain times, dealmakers and their counsel have many burning questions surrounding...more

McDermott Will & Emery

Private Client & Wealth Management - Issue 1 - 2019

McDermott Will & Emery on

IN THIS ISSUE - Alongside the usual challenges of rising and falling values inherent in any family-owned asset, cryptocurrency, which is kept in key-protected digital wallets, is prone to getting lost or disappearing with...more

Mintz Edge

Issues in Chinese Foreign Direct Investment in U.S. Early Stage Biotechnology Companies

Mintz Edge on

There has been a marked increase in the amount of money being invested by Chinese investors into U.S. early stage biotechnology companies since 2017, spurred on by direct encouragement from Beijing through its Made in China...more

6 Results
 / 
View per page
Page: of 1

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
Sign up Log in
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
- hide
- hide